Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alefacept Clear all
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

NCT00832585
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

NCT01163799
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alefacept (ASP0485)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

NCT00678470
View directory record Official record
Conditions
Moderate to Severe Psoriasis
Interventions
Intralesional Alefacept
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822
View directory record Official record
Conditions
Pharmacokinetics of Alefacept
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated No phase listed Observational

AMEVIVE® Pregnancy Registry

NCT00342862
View directory record Official record
Conditions
Pregnancy
Interventions
Amevive exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 4 Interventional

Community Based Trial for AMEVIVE®

NCT00168753
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

NCT00674063
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
11
States / cities
Hot Springs, Arkansas • Fridley, Minnesota • Omaha, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102
View directory record Official record
Conditions
Alopecia Areata
Interventions
Alefacept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Alefacept Mechanism of Action in Psoriasis

NCT00150982
View directory record Official record
Conditions
Psoriasis
Interventions
Mechanism of action of alefacept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 4 Interventional

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

NCT00493324
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept, polyvalent pneumococcal vaccine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Alefacept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

NCT00808223
View directory record Official record
Conditions
Psoriasis
Interventions
alefacept
Biological
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
San Diego, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated No phase listed Observational

Assessment and Tracking of Long-term Alefacept Safety

NCT00454701
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT00438802
View directory record Official record
Conditions
Lymphoma
Interventions
Alefacept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
3
States / cities
Duarte, California • Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

NCT00543569
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

NCT00135733
View directory record Official record
Conditions
Lichen Planus
Interventions
Amevive (Alefacept), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Transitioning From Cyclosporine to Alefacept in Psoriasis

NCT00143806
View directory record Official record
Conditions
Psoriasis
Interventions
Transitioning patients from cyclosporine to alefacept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2009 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Alefacept in Patients With Relapsed/Refractory Aplastic Anemia

NCT01267643
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 17, 2026, 9:40 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

NCT00815633
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
Alefacept
Drug
Lead sponsor
Joshua Zeichner
Other
Eligibility
30 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 17, 2026, 9:40 AM EDT
Withdrawn Not applicable Interventional

Alefacept in Kidney Transplant Recipients

NCT01433770
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Amevive
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 17, 2026, 9:40 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Irvine, California • San Francisco, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 17, 2026, 9:40 AM EDT